Q &A on potential use of BET inhibitors for FSHD
Publicado el marzo 15th, 20173/15/17
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy (FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits bromodomain […]
Archivado en: Investigación sobre la FSHD